MGTX MeiraGTx Holdings plc

MeiraGTx to Participate in Upcoming Investor Conferences

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

  • Morgan Stanley 20th Annual Global Healthcare Conference

Fireside Chat: Wednesday, September 14, 2022, at 3:30 p.m. ET

  • Chardan's 6th Annual Genetic Medicines Conference

Panel Discussion: “Gene Regulation”, Tuesday, October 4, 2022, at 9:30 a.m. ET

Fireside Chat: Tuesday, October 4, 2022, at 10:30 a.m. ET

A live webcast of the fireside chats will be available on the Investors page of the Company’s website at . Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology which allows tight, dose responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit

Contacts



Investors:

MeiraGTx

Media:

Jason Braco, Ph.D.

LifeSci Communications



EN
08/09/2022

Underlying

MGTXMeiraGTx Holdings plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MeiraGTx Holdings plc

 PRESS RELEASE
Free
MGTX MeiraGTx Holdin...

MeiraGTx Announces the Presentation of Four Posters at the American So...

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2...

May 13, 2025 1 EN
 PRESS RELEASE
Free
MGTX MeiraGTx Holdin...

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Reports First Quarter 2025 Financial and Operational Results -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson’s disease -  Gained alignme...

May 13, 2025 1 EN
 PRESS RELEASE
Free
MGTX MeiraGTx Holdin...

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Des...

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (N...

May 9, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.79
ZBH ZIMMER BIOMET H...
ATNI ATN Internation... ... (+38)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ZBH ZIMMER BIOMET HOLDINGS INC.
ATNI ATN INTERNATIONAL INC.
VZ VERIZON COMMUNICATIONS INC.
SYNL SYNALLOY CORP.
SCCO SOUTHERN COPPER CORPORATION
RGR STURM RUGER & COMPANY INC.
MRCY MERCURY SYSTEMS INC.
MKTX MARKETAXESS HOLDINGS INC.
KR KROGER CO.
FCX FREEPORT-MCMORAN INC.
EIG EMPLOYERS HOLDINGS INC.
DG DOLLAR GENERAL CORPORATION
CBOE CBOE GLOBAL MARKETS INC
ALL ALLSTATE CORPORATION
R1D AERCAP HOLDINGS NV
FNF FIDELITY NATIONAL FINANCIAL INC. - FNF GROUP
CNR. CANADIAN NATIONAL RAILWAY COMPANY
DGICA DONEGAL GROUP INC. CL A
LFVN LIFEVANTAGE
BRK.B BERKSHIRE HATHAWAY INC. CLASS B
HRTG HERITAGE INSURANCE HOLDINGS INC.
THG HANOVER INSURANCE GROUP INC.
FTG111 FLATEXDEGIRO AG
PAGS PAGSEGURO DIGITAL LTD
MGTX MEIRAGTX HOLDINGS PLC
OPRX OPTIMIZERX CORP
GRPN GROUPON INC.
RKT ROCKET COMPANIES
AVAH AVEANNA HEALTHCARE HLDGS INC
RGC REGENCELL BIOSCIENCE HLDGS LTD
QBTS D-WAVE QUANTUM INC.
ANG ANGLOGOLD ASHANTI LIMITED
METC RAMACO RESOURCES INC.
NXT NEXT GEOSOLUTIONS EUROPE S.P.A.
BNTC BENITEC BIOPHARMA INC
SARO STANDARDAERO INC.
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
USAU US GOLD CORP
03/14/25 March 14, 2025 1 EN
 PRESS RELEASE
Free
MGTX MeiraGTx Holdin...

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Opera...

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates -  Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease -  MeiraGTx and Hologen have created the first neuro-AI clinical drug development company to transform the discovery and development of therapies targeting CNS circ...

March 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch